Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BMS-986165 on Rosuvastatin PK
NCT03044873Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration of Rosuvastatin, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration of Rosuvastatin and 1 more. Started Feb 2017; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03044873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03044873.